| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €16.60 |
| 52 Week High | €18.00 |
| 52 Week Low | €13.58 |
| Beta | 1.09 |
| 11 Month Change | 14.96% |
| 3 Month Change | 8.21% |
| 1 Year Change | 4.14% |
| 33 Year Change | -50.96% |
| 5 Year Change | -4.60% |
| Change since IPO | 120.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILM1 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0.2% | -0.5% | -0.1% |
| 1Y | 4.1% | -2.1% | 2.3% |
Return vs Industry: ILM1 exceeded the German Healthcare industry which returned -0.9% over the past year.
Return vs Market: ILM1 exceeded the German Market which returned 2% over the past year.
Price Volatility
| ILM1 volatility | |
|---|---|
| ILM1 Average Weekly Movement | 5.5% |
| Healthcare Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ILM1 has not had significant price volatility in the past 3 months.
Volatility Over Time: ILM1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 500 | Matthias Gaertner | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
Medios AG Fundamentals Summary
| ILM1 fundamental statistics | |
|---|---|
| Market cap | €411.73m |
| Earnings (TTM) | €17.97m |
| Revenue (TTM) | €1.81b |
22.9x
P/E Ratio0.2x
P/S RatioIs ILM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILM1 income statement (TTM) | |
|---|---|
| Revenue | €1.81b |
| Cost of Revenue | €1.70b |
| Gross Profit | €107.44m |
| Other Expenses | €89.47m |
| Earnings | €17.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 5.94% |
| Net Profit Margin | 0.99% |
| Debt/Equity Ratio | 0% |
How did ILM1 perform over the long term?
See historical performance and comparison